Research programme: multiple sclerosis therapies - Provid

Drug Profile

Research programme: multiple sclerosis therapies - Provid

Alternative Names: PV-072; PV-267

Latest Information Update: 25 Oct 2013

Price : $50

At a glance

  • Originator Provid Pharmaceuticals
  • Developer Provid Pharmaceuticals; University of Texas Health Science Center at San Antonio
  • Class Small molecules
  • Mechanism of Action HLA-DR antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple sclerosis

Most Recent Events

  • 15 Oct 2013 Preclinical development is ongoing in USA
  • 14 Jan 2004 Provid and Suntory have entered into an agreement to co-develop small peptide mimetic inhibitors of antigen presentation by MHC class II DR2 molecules in the US for multiple sclerosis
  • 06 Aug 2003 Preclinical trials in Multiple sclerosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top